Martin Emilio L.
- Country
- Spain
- Department
- #2609: Urology
Research Overview
- A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- Phase II Study of Sasanlimab and Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients
- Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 219 of 470 partner sites.
Specializations
Lung Cancer Specialization
This investigator demonstrates extensive involvement in treating various forms of lung cancer, with particular focus on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Their research encompasses both early-stage and advanced disease states.
- Resectable NSCLC
- Metastatic Squamous NSCLC
- Extensive-stage SCLC
- Pancoast Tumors
Molecular-Targeted Therapies
The investigator works with targeted therapeutic approaches focusing on specific genetic mutations and molecular pathways in cancer treatment, particularly in EGFR-mutated and RET fusion-positive lung cancers.
- KRAS G12C Mutations
- MET Overexpression
- EGFR Mutations
- RET Fusion Studies
Urological Oncology
The investigator's expertise extends to urological cancers, including innovative approaches in treating prostate cancer and bladder cancer.
- Castration-Resistant Prostate Cancer
- Non-Muscle Invasive Bladder Cancer
- Renal Cell Carcinoma
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.